1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzoimidazole-5-carboxylic acid | 474019-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzoimidazole-5-carboxylic acid
• 英文别名: 1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzimidazole-5-carboxylic acid；1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]benzimidazole-5-carboxylic acid
• CAS: 474019-87-9
• 化学式: C₂₁H₂₂N₂O₃
• 分子量: 350.417
• InChiKey: WPUCAQMFSMHQBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzoimidazole-5-carboxylic acid 在 氨 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2-(4-ethoxybenzyl)-1-(cyclopropylmethyl)-1H-benzo[d]imidazole-5-carboxamide
  参考文献：
  名称：

  Novel benzimidazole derivatives as selective CB2 agonists

  摘要：

  The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (> 1000-fold) over the CB1 receptor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.073
• 作为产物：
  描述：

  1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzimidazole-5-carbonitrile 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 生成 1-(cyclopropylmethyl)-2-(4-ethoxybenzyl)-1H-benzoimidazole-5-carboxylic acid
  参考文献：
  名称：

  Novel benzimidazole derivatives as selective CB2 agonists

  摘要：

  The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (> 1000-fold) over the CB1 receptor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.073

文献信息

• Novel compounds
  申请人：——

  公开号：US20040116465A1

  公开（公告）日：2004-06-17

  Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. 1

  本申请披露和声明一般式(I)的化合物，以及包括这些新化合物的盐和药物组合物，以及它们在治疗中的用途，特别是在疼痛管理方面。
• Compounds
  申请人：AstraZeneca AB

  公开号：US07030139B2

  公开（公告）日：2006-04-18

  Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain

  本申请公开和声明一般式(I)的化合物，以及包含这些新化合物的盐和药物组合物，以及它们在治疗中的应用，特别是在疼痛管理方面。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1390350A1

  公开（公告）日：2004-02-25
• US7030139B2
  申请人：——

  公开号：US7030139B2

  公开（公告）日：2006-04-18
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2002085866A1

  公开（公告）日：2002-10-31

  Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.